EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudieOpen Access · CC BY 4.0

Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records

Christopher F Bell iD, Daniel C Gibbons, Myriam Drysdale, Helen J Birch, Emily J Lloyd, Vishal Patel, Corinne Carpenter, Katherine Carlson iD, Ediz S Calay, Arjun Puranik, Tyler E Wagner, John C O'Horo iD und 1 weitere

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0304822 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift PLOS ONE, 2024. Verfasst von Christopher F Bell und 12 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Durham, North Carolina, United States of America. Hauptthemen laut MEDLINE: Hospitalization, Antibodies, Monoclonal, Humanized, COVID-19, Electronic Health Records. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK and Vir Biotechnology, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To describe outcomes of high-risk patients with coronavirus disease 2019 (COVID-19) treated with sotrovimab, other monoclonal antibodies (mAbs), or antivirals, and patients who did not receive early COVID-19 treatment. We also evaluate the comparative effectiveness of sotrovimab versus no treatment in preventing severe clinical outcomes.

Methods

This observational retrospective cohort study analyzed Mayo Clinic electronic health records. Non-hospitalized adult patients diagnosed with COVID-19 from May 26, 2021 and April 23, 2022 and at high risk of COVID-19 progression were eligible. The primary outcome was 29-day all-cause hospitalization and/or death. Outcomes were described for patients treated with sotrovimab, other mAbs, or antivirals, and eligible but untreated patients, and compared between sotrovimab-treated and propensity score (PS)-matched untreated cohorts.

Results

We included 35,485 patients (sotrovimab, 1369; other mAbs, 6488; antivirals, 133; high-risk untreated, 27,495). A low proportion of patients treated with sotrovimab (n = 33/1369, 2.4%), other mAbs (n = 147/6488, 2.3%), or antivirals (n = 2/133, 1.5%) experienced all-cause hospitalization or death. Among high-risk untreated patients, the percentage of all-cause hospitalization or death was 3.3% (n = 910/27,495). In the PS-matched analysis, 2.5% (n = 21/854) of sotrovimab-treated patients experienced all-cause hospitalization and/or death versus 2.8% (n = 48/1708) of untreated patients (difference, –0.4%; p = 0.66). Significantly fewer sotrovimab-treated patients required intensive care unit admission (0.5% vs 1.8%; difference, –1.3%; p = 0.002) or respiratory support (3.5% vs 8.7%; difference, –5.2%; p < 0.001).

Conclusions

There was no significant difference in the proportion of sotrovimab-treated and PS-matched untreated patients experiencing 29-day all-cause hospitalization or mortality, although significantly fewer sotrovimab-treated patients required intensive care unit admission or respiratory support.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HospitalizationAntibodies, Monoclonal, HumanizedCOVID-19Electronic Health RecordsCOVID-19 Drug TreatmentAntiviral AgentsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesUnited StatesSARS-CoV-2AdultAged, 80 and overTreatment OutcomeCohort StudiesAntibodies, Neutralizing

Substanzen

Antibodies, Monoclonal, HumanizedAntiviral AgentsbamlanivimabAntibodies, Neutralizing

Autor:innen und Institutionen

  • GSK, Durham, North Carolina, United States of America.
  • GSK, Brentford, United Kingdom.
  • nference, Cambridge, Massachusetts, United States of America.
  • Mayo Clinic, Rochester, Minnesota, United States of America.

ORCID-Profile: Christopher F Bell, Katherine Carlson, John C O'Horo

Förderung

  • GSK and Vir Biotechnology, Inc

Zitieren

APA

Bell, C. F., Gibbons, D. C., Drysdale, M., Birch, H. J., Lloyd, E. J., Patel, V., Carpenter, C., Carlson, K., Calay, E. S., Puranik, A., Wagner, T. E., O'Horo, J. C., & Razonable, R. R. (2024). Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records. PLOS ONE. https://doi.org/10.1371/journal.pone.0304822

Vancouver

Bell CF, Gibbons DC, Drysdale M, Birch HJ, Lloyd EJ, Patel V, et al. Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records. PLOS ONE. 2024. doi:10.1371/journal.pone.0304822

BibTeX
@article{Bell2024,
  author = {Bell, Christopher F and Gibbons, Daniel C and Drysdale, Myriam and Birch, Helen J and Lloyd, Emily J and Patel, Vishal and Carpenter, Corinne and Carlson, Katherine and Calay, Ediz S and Puranik, Arjun and Wagner, Tyler E and O'Horo, John C and Razonable, Raymund R},
  title = {Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0304822}
}
Kostenlos starten →